Based on a multiplatform analysis of structural genomic abnormalities and gene expression in 574 DLBCL biopsy samples, a molecular classification of DLBCL was proposed that includes four subtypes, termed the MCD (MYD88L265P- and CD79B-co-mutated) subtype, the BN2 (BCL6-fusions or NOTCH2- mutated) subtype, the N1 (NOTCH1-mutated) subtype, and the EZH2 (based on EZH2 mutations and BCL2 translocations) subtype, whereas a significant number of cases remained unclassified [7]. The gene discussed is CD79B; the disease is diffuse large B-cell lymphoma.